Deuterated benzo[D][1,3]-dioxol derivatives
The present invention relates to an isotopologue of Compound 1 substituted with deuterium at the methylene carbon of the benzodioxol ring. The isotopologues of this invention selective serotonin reuptake inhibitors (SSRIs) and possess unique biopharmaceutical and metabolic properties compared to Compound 1. They may also be used to accurately determine the concentration of Compound 1 in biological fluids and to determine metabolic patterns of Compound 1 and its isotopologues. The invention further provides compositions comprising these deuterated isotopologues and methods of treating diseases and conditions that are responsive to increased neuronal serotonin transmission, alone and in combination with additional agents.
1. An isolated compound of formula I:
or a pharmaceutically acceptable salt thereof; wherein:
D is deuterium;
Y 1 is deuterium;
each of Y 2 and Y 3 are independently selected from deuterium and hydrogen; and
each hydrogen is independently optionally replaced with deuterium; and
wherein at least 90% of the compound has a deuterium atom at each position designated as deuterium in formula I.
2. The isolated compound according to claim 1 , wherein up to 4 hydrogen atoms are replaced by deuterium.
3. The isolated compound according to claim 1 , wherein at least one of Y 2 and Y 3 is independently deuterium.
4. The isolated compound according to claim 1 , wherein both Y 2 and Y 3 are deuterium.
5. The isolated compound according to claim 1 , wherein the compound is selected from any one of:
or a pharmaceutically acceptable salt thereof.
6. The compound of claim 5 , wherein all hydrogen atoms are present at their natural isotopic abundance.